Antonin is currently Chief Executive Officer of Evox Therapeutics. Prior to this Antonin held several senior R&D leadership roles including Chief Scientific Officer of Ablynx, Chief Scientific Officer of Moderna Therapeutics and Vice President, Research, Immunology, Metabolic, and Viral Disease at Alnylam Pharmaceuticals. After completing his PhD in Immunology at Harvard University, Antonin was a research fellow at the Wellcome Trust Immunology Unit, University of Cambridge.